That CaV3.1 is an established clinical drug target to treat human breast cancer and that CaV3.1 antagonists inhibit weight gain in mice suggest that modulation of this CaV may be beneficial in the regulation of secondary sexual characteristic functions. Here, CACNA1G is linked to breast cancer.